recombinant human igg1 monoclonal antibody cixutumumab formerly imc-a12 (ImClone Inc)
90
Structured Review
ImClone Inc
recombinant human igg1 monoclonal antibody cixutumumab formerly imc-a12
Recombinant Human Igg1 Monoclonal Antibody Cixutumumab Formerly Imc A12, supplied by ImClone Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/imc-a12+antibody/imc+a12+antibody/pmc09955633-107-0-8
Average 90 stars, based on 1 article reviews
Recombinant Human Igg1 Monoclonal Antibody Cixutumumab Formerly Imc A12, supplied by ImClone Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/imc-a12+antibody/imc+a12+antibody/pmc09955633-107-0-8
Average 90 stars, based on 1 article reviews
recombinant human igg1 monoclonal antibody cixutumumab formerly imc-a12 - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma"
Article Title: Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
Journal: Current Oncology
doi: 10.3390/curroncol30020105
Figure Legend Snippet: Clinical trials on targeted therapy in hepatocellular carcinoma recurrence.
Techniques Used: Clinical Proteomics, Virus, Infection
Related Articles
Control:Article Title: Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment Article Snippet: IMC-A12 (10 mg/ml), a Article Title: Chemotherapy and targeted agents for thymic malignancies. Article Snippet: www.expert-reviews.com ISSN 1473-7140 © 2012 Expert Reviews Ltd 10.1586/ERA.12.29 Thymic malignancies represent a wide range of clinical, histologic and molecular entities that may be aggressive and difficult to treat [1–4].. The current histopathologic classification distinguishes thymomas (types A, AB, B1, B2 and B3) and thymic carcinoma based upon the morphology of epithelial tumor cells (with an increasing degree of atypia from type A to thymic carcinoma), the relative proportion of the nontumoral lymphocytic component (decreasing from types B1 to B3) and resemblance to normal thymic architecture [2].. Tumor invasiveness as evaluated by the Masaoka staging system is a major predictor of outcome [5,6]. Article Title: Combination drug therapy for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Insulin-like Growth Factor-II (IGF-II) and IGF-II Analogs with Enhanced Insulin Receptor-a Binding Affinity Promote Neural Stem Cell Expansion Article Snippet: In some experiments, the functional Article Title: Compositions for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Circulating tumor cell assay Article Snippet: Other Article Title: The Pathophysiology of Thyroid Eye Disease (TED): Implications for Immunotherapy Article Snippet: Figitumumab (CP-751,871) is a blocking anti-IGF-1R antibody currently undergoing phase III clinical trials in patients with non-small cell lung cancers, and Staining:Article Title: Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment Article Snippet: IMC-A12 (10 mg/ml), a Article Title: Chemotherapy and targeted agents for thymic malignancies. Article Snippet: www.expert-reviews.com ISSN 1473-7140 © 2012 Expert Reviews Ltd 10.1586/ERA.12.29 Thymic malignancies represent a wide range of clinical, histologic and molecular entities that may be aggressive and difficult to treat [1–4].. The current histopathologic classification distinguishes thymomas (types A, AB, B1, B2 and B3) and thymic carcinoma based upon the morphology of epithelial tumor cells (with an increasing degree of atypia from type A to thymic carcinoma), the relative proportion of the nontumoral lymphocytic component (decreasing from types B1 to B3) and resemblance to normal thymic architecture [2].. Tumor invasiveness as evaluated by the Masaoka staging system is a major predictor of outcome [5,6]. Article Title: Combination drug therapy for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Insulin-like Growth Factor-II (IGF-II) and IGF-II Analogs with Enhanced Insulin Receptor-a Binding Affinity Promote Neural Stem Cell Expansion Article Snippet: In some experiments, the functional Article Title: Compositions for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Circulating tumor cell assay Article Snippet: Other Article Title: The Pathophysiology of Thyroid Eye Disease (TED): Implications for Immunotherapy Article Snippet: Figitumumab (CP-751,871) is a blocking anti-IGF-1R antibody currently undergoing phase III clinical trials in patients with non-small cell lung cancers, and Transfection:Article Title: Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment Article Snippet: IMC-A12 (10 mg/ml), a Article Title: Chemotherapy and targeted agents for thymic malignancies. Article Snippet: www.expert-reviews.com ISSN 1473-7140 © 2012 Expert Reviews Ltd 10.1586/ERA.12.29 Thymic malignancies represent a wide range of clinical, histologic and molecular entities that may be aggressive and difficult to treat [1–4].. The current histopathologic classification distinguishes thymomas (types A, AB, B1, B2 and B3) and thymic carcinoma based upon the morphology of epithelial tumor cells (with an increasing degree of atypia from type A to thymic carcinoma), the relative proportion of the nontumoral lymphocytic component (decreasing from types B1 to B3) and resemblance to normal thymic architecture [2].. Tumor invasiveness as evaluated by the Masaoka staging system is a major predictor of outcome [5,6]. Article Title: Combination drug therapy for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Insulin-like Growth Factor-II (IGF-II) and IGF-II Analogs with Enhanced Insulin Receptor-a Binding Affinity Promote Neural Stem Cell Expansion Article Snippet: In some experiments, the functional Article Title: Compositions for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Circulating tumor cell assay Article Snippet: Other Article Title: The Pathophysiology of Thyroid Eye Disease (TED): Implications for Immunotherapy Article Snippet: Figitumumab (CP-751,871) is a blocking anti-IGF-1R antibody currently undergoing phase III clinical trials in patients with non-small cell lung cancers, and Activity Assay:Article Title: Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment Article Snippet: IMC-A12 (10 mg/ml), a Article Title: Chemotherapy and targeted agents for thymic malignancies. Article Snippet: www.expert-reviews.com ISSN 1473-7140 © 2012 Expert Reviews Ltd 10.1586/ERA.12.29 Thymic malignancies represent a wide range of clinical, histologic and molecular entities that may be aggressive and difficult to treat [1–4].. The current histopathologic classification distinguishes thymomas (types A, AB, B1, B2 and B3) and thymic carcinoma based upon the morphology of epithelial tumor cells (with an increasing degree of atypia from type A to thymic carcinoma), the relative proportion of the nontumoral lymphocytic component (decreasing from types B1 to B3) and resemblance to normal thymic architecture [2].. Tumor invasiveness as evaluated by the Masaoka staging system is a major predictor of outcome [5,6]. Article Title: Combination drug therapy for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Insulin-like Growth Factor-II (IGF-II) and IGF-II Analogs with Enhanced Insulin Receptor-a Binding Affinity Promote Neural Stem Cell Expansion Article Snippet: In some experiments, the functional Article Title: Compositions for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Circulating tumor cell assay Article Snippet: Other Article Title: The Pathophysiology of Thyroid Eye Disease (TED): Implications for Immunotherapy Article Snippet: Figitumumab (CP-751,871) is a blocking anti-IGF-1R antibody currently undergoing phase III clinical trials in patients with non-small cell lung cancers, and In Vitro:Article Title: Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment Article Snippet: IMC-A12 (10 mg/ml), a Article Title: Chemotherapy and targeted agents for thymic malignancies. Article Snippet: www.expert-reviews.com ISSN 1473-7140 © 2012 Expert Reviews Ltd 10.1586/ERA.12.29 Thymic malignancies represent a wide range of clinical, histologic and molecular entities that may be aggressive and difficult to treat [1–4].. The current histopathologic classification distinguishes thymomas (types A, AB, B1, B2 and B3) and thymic carcinoma based upon the morphology of epithelial tumor cells (with an increasing degree of atypia from type A to thymic carcinoma), the relative proportion of the nontumoral lymphocytic component (decreasing from types B1 to B3) and resemblance to normal thymic architecture [2].. Tumor invasiveness as evaluated by the Masaoka staging system is a major predictor of outcome [5,6]. Article Title: Combination drug therapy for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Insulin-like Growth Factor-II (IGF-II) and IGF-II Analogs with Enhanced Insulin Receptor-a Binding Affinity Promote Neural Stem Cell Expansion Article Snippet: In some experiments, the functional Article Title: Compositions for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Circulating tumor cell assay Article Snippet: Other Article Title: The Pathophysiology of Thyroid Eye Disease (TED): Implications for Immunotherapy Article Snippet: Figitumumab (CP-751,871) is a blocking anti-IGF-1R antibody currently undergoing phase III clinical trials in patients with non-small cell lung cancers, and Functional Assay:Article Title: Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment Article Snippet: IMC-A12 (10 mg/ml), a Article Title: Chemotherapy and targeted agents for thymic malignancies. Article Snippet: www.expert-reviews.com ISSN 1473-7140 © 2012 Expert Reviews Ltd 10.1586/ERA.12.29 Thymic malignancies represent a wide range of clinical, histologic and molecular entities that may be aggressive and difficult to treat [1–4].. The current histopathologic classification distinguishes thymomas (types A, AB, B1, B2 and B3) and thymic carcinoma based upon the morphology of epithelial tumor cells (with an increasing degree of atypia from type A to thymic carcinoma), the relative proportion of the nontumoral lymphocytic component (decreasing from types B1 to B3) and resemblance to normal thymic architecture [2].. Tumor invasiveness as evaluated by the Masaoka staging system is a major predictor of outcome [5,6]. Article Title: Combination drug therapy for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Insulin-like Growth Factor-II (IGF-II) and IGF-II Analogs with Enhanced Insulin Receptor-a Binding Affinity Promote Neural Stem Cell Expansion Article Snippet: In some experiments, the functional Article Title: Compositions for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Circulating tumor cell assay Article Snippet: Other Article Title: The Pathophysiology of Thyroid Eye Disease (TED): Implications for Immunotherapy Article Snippet: Figitumumab (CP-751,871) is a blocking anti-IGF-1R antibody currently undergoing phase III clinical trials in patients with non-small cell lung cancers, and Blocking Assay:Article Title: Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment Article Snippet: IMC-A12 (10 mg/ml), a Article Title: Chemotherapy and targeted agents for thymic malignancies. Article Snippet: www.expert-reviews.com ISSN 1473-7140 © 2012 Expert Reviews Ltd 10.1586/ERA.12.29 Thymic malignancies represent a wide range of clinical, histologic and molecular entities that may be aggressive and difficult to treat [1–4].. The current histopathologic classification distinguishes thymomas (types A, AB, B1, B2 and B3) and thymic carcinoma based upon the morphology of epithelial tumor cells (with an increasing degree of atypia from type A to thymic carcinoma), the relative proportion of the nontumoral lymphocytic component (decreasing from types B1 to B3) and resemblance to normal thymic architecture [2].. Tumor invasiveness as evaluated by the Masaoka staging system is a major predictor of outcome [5,6]. Article Title: Combination drug therapy for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Insulin-like Growth Factor-II (IGF-II) and IGF-II Analogs with Enhanced Insulin Receptor-a Binding Affinity Promote Neural Stem Cell Expansion Article Snippet: In some experiments, the functional Article Title: Compositions for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Circulating tumor cell assay Article Snippet: Other Article Title: The Pathophysiology of Thyroid Eye Disease (TED): Implications for Immunotherapy Article Snippet: Figitumumab (CP-751,871) is a blocking anti-IGF-1R antibody currently undergoing phase III clinical trials in patients with non-small cell lung cancers, and Clinical Proteomics:Article Title: Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment Article Snippet: IMC-A12 (10 mg/ml), a Article Title: Chemotherapy and targeted agents for thymic malignancies. Article Snippet: www.expert-reviews.com ISSN 1473-7140 © 2012 Expert Reviews Ltd 10.1586/ERA.12.29 Thymic malignancies represent a wide range of clinical, histologic and molecular entities that may be aggressive and difficult to treat [1–4].. The current histopathologic classification distinguishes thymomas (types A, AB, B1, B2 and B3) and thymic carcinoma based upon the morphology of epithelial tumor cells (with an increasing degree of atypia from type A to thymic carcinoma), the relative proportion of the nontumoral lymphocytic component (decreasing from types B1 to B3) and resemblance to normal thymic architecture [2].. Tumor invasiveness as evaluated by the Masaoka staging system is a major predictor of outcome [5,6]. Article Title: Combination drug therapy for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Insulin-like Growth Factor-II (IGF-II) and IGF-II Analogs with Enhanced Insulin Receptor-a Binding Affinity Promote Neural Stem Cell Expansion Article Snippet: In some experiments, the functional Article Title: Compositions for the treatment of solid tumors Article Snippet: 11:944s-950s; or being developed by Article Title: Circulating tumor cell assay Article Snippet: Other Article Title: The Pathophysiology of Thyroid Eye Disease (TED): Implications for Immunotherapy Article Snippet: Figitumumab (CP-751,871) is a blocking anti-IGF-1R antibody currently undergoing phase III clinical trials in patients with non-small cell lung cancers, and |